The projected fair value for CRISPR Therapeutics is US$83.24 based on 2 Stage Free Cash Flow to Equity CRISPR Therapeutics' US$45.55 share price signals that it might be 45% undervalued The analyst ...

Back in 1900 the life expectancy of people with Down Syndrome was 9 years. In 1984, it was 28 years, today it's leveled off ...

These cells came from a person with Gitelman-like syndrome, a disorder linked to mitochondrial dysfunction. The correction ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations ...

A new study highlights a historic step in personalized medicine, utilizing CRISPR gene-editing technology for a ...

Moving toward clinical development, the researchers demonstrated efficient delivery of mRNA mitochondrial base editors using lipid nanoparticles.

Scientific organizations recently called for a 10-year ban on human germline editing. But will we ever be ready? And how ...

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

They also found that after the extra chromosome was removed, genes tied to nervous system development were more active and ...

A novel, portable assay can deliver TB diagnoses in under an hour at low cost using samples of blood, saliva, or sputum, ...